Loading...
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Holman, Rury R. Bethel, Mary A. Chan, Juliana C. N. Chiasson, Jean Louis Doran, Zoë Ge, Junbo Gerstein, Hertzel C. Huo, Yong McMurray, John J. Ryden, Lars
Holman, Rury R.
Bethel, Mary A.
Chan, Juliana C. N.
Chiasson, Jean Louis
Doran, Zoë
Ge, Junbo
Gerstein, Hertzel C.
Huo, Yong
McMurray, John J.
Ryden, Lars
Abstract
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus ( T2DM ). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.
Keywords
Date
2014
Type
Journal article
Journal
American Heart Journal
Book
Volume
168
Issue
1
Page Range
23-29
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
License
File Access
Controlled